Thur 8 May
0745 - 0845
1A Epilepsy | 1C Neuro Infection | 3A Peripheral Nerve | 3B TBI
Epilepsy
1A Chair: Lina Nashef
Paul Cooper: Predicting risk of epilepsy per year post head injury: When would DVLA requirements be met and when can driving resume? A neurologist’s guide
Tony Marson: Factors predicting recurrence after anti-seizure medication withdrawal and likelihood of regaining control in the event of recurrence
William Stern: An update on studies on valproate and possible transgenerational effect in men – how to safely navigate the uncertainty
Dorothy Joe: Surgery for epilepsy for low grade lesions in neuro-oncology practice – A missed opportunity?
Neuro Infection
1C Clinical Challenges in the Investigation and Management of Encephalitis
1C Chair: Benedict Michael
Benedict Michael: Welcome and Introduction
Bhagteshwar Singh, Liverpool: Encephalitis in the returning traveller
Laura Benjamin, UCL: Encephalitis in the immuncompromised
Matt Jones, Manchester: Autoimmune encephalitis challenge
Peripheral Nerve
3A Diabetic Neuropathies: Making it Painless
Sponsored by Alnylam & Argenx – Teas/Coffee & pastries provided
Chair: Tim Lavin
Matthew Evans: Small Fibre Neuropathies
Arjuna Nagendran: An approach to conduction slowing in a diabetic: Could it be CIDP?
TBI
3B Chairs: Peter Jenkins & Lucia Li
James Mitchell, Birmingham: Management of acute and prolonged post-concussion symptoms
Damian Jenkins, Oxford: Distinguishing trauma in traumatic brain injury: military case studies
Thomas Parker, Imperial: Brain health outcomes in retired professional rugby and football players (the Advanced Brain Health Clinic study)
Fri 9 May
0750 - 0850
1A Cognitive | 1C Autonomic | 3A FND | 3B Neuro-oncology
Cognitive
1A Oncological interventions for Glioma – Time to involve the neurologist?
1A Chair: Akram Hosseini
Mark Ellul: Long-term cognitive outcomes after autoimmune encephalitis
Benedict Michael: Longer-term cognitive consequences after COVID infection
Ava Easton: Cognitive challenges following autoimmune encephalitis
Autonomic
1C Biomarkers of Early Autonomic Disease
1A Chair: Gordon Ingle
Gordon Ingle, Valeria Iodice, Patricia McNamara and Giacomo Chiaro present an overview of existing biomarkers and how these can be used in early assessment of autonomic failure. The session will involve interactive discussion, giving examples and case studies. The speakers will update on progress to make Droxidopa available for neurological use via NHS England and share plans for a UK wide Autonomic MDT and a UK Autonomic Society to work alongside the Special Interest Group.
FND
3A What should an FND service look like?
1A Chair: Marianne Novak
Marianne Novak, Beth Mallam & Christine Burness
The structure of FND services varies across existing UK services, while many regions do not have an FND service at all. There is significant inequality of access to specialist healthcare for people with FND as a result. We would like to (a) present three UK FND services as examples of different models, and (b) discuss what makes a successful FND service, what challenges are faced in developing and sustaining these services, and what are the ways in which we can support each other in developing new services.
Neuro-oncology
3B Oncological interventions for Glioma – Time to involve the neurologist?
1A Chair: Shanika Samarasekera
Satheesh Ramalingam, Birmingham: Is it a tumour? Identifying radiologically- challenging lesions
Catherine McBain, Manchester: The potential benefits and side effects of Vorasidenib for the treatment of Low Grade Glioma- local experience
Sara Meade, Birmingham: Indigo and beyond: An overview of the Vorasidenib trials and their implications for service delivery in neuro-oncology
Round table discussion: Should neurologists deliver oncological therapies – Is it time for a reconfiguration of services?